Úloha aprepitantu v antiemetické profylaxi z perspektivy doporučených postupů a úhradového omezení
| Title in English | The role of aprepitant in antiemetic prophylaxis from the perspective of best practices and restrictions of reimbursement |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Antiemetics News |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | aprepitant; chemotherapy induced nausea and vomiting |
| Description | Aprepitant, an inhibitor of substance P on NK1 receptors with strong antiemetic effect in patients treated with chemotherapy, is currently indicated for primary prophylaxis in patients with highly emetogenic chemotherapy, including combination of anthracyclin and cyclophosphamide, a 3-drug combination with serotonin inhibitor and dexamethasone. Combinations with aprepilant significantly improve antiemetic efficacy in comparison with all types of prophylaxis used to date particularly in delayed phase after chemotherapy. The effect is apparent even in acute phase, especially after AC combination. Effective prevention of nausea and vomiting from the first cycle of emetogenic chemotherapy according to the international guidelines can prevent senous complications and reductions of anticancer treatment and contribute to better outcome. |